Neurite

LM11A-31 dihydrochloride is a water-soluble, non-peptide with high blood-brain barrier permeability.LM11A-31 dihydrochloride, a p75NTR (neurotrophin receptor p75) Ligand, is a potent proNGF (nerve growth factor) antagonist.

1. Negletein (7-O-Methylbaicalein) has anti-inflammatory and immunomodulatory activities via inhibition of TNF-α, iNOS and IL-1β. 2. Negletein as a neuroprotectant enhances the action of nerve growth factor and induces neurite outgrowth in PC12 cells. 3. Negletein shows a comparable redox-active potential, and it (50 μM, 4 h) can activate Nrf2. 4. Negletein shows significant antimicrobial activity. 5. Negletein has anti-hypoxia activity, it can significantly prolong the survival time of hypoxic mice.6. Negletein has anti- Alzheimer's disease activity, it inhibits the iron-dependent formation of ROS and also blocks the iron-induced oligomerization of amyloid beta 42 in vitro. 7. Negletein (IC50: 3.89 +/- 0.39 microM) exhibits potent inhibitory activity against nuclear factor of activated T cells (NFAT) transcription factor.

1. Nardosinone has inhibitory effect on Ang II-induced hypertrophy in H9c2 cells, might be mediated by targeting PI3K/Akt and MEK/ERK signaling pathways. 2. Nardosinone could protect against the neuronal injury exposed to OGD, which may be relevant to the

Deoxyandrographolide (14-deoxyandrographolide) potentiates NGF-induced neurite outgrowth. Deoxyandrographolide suppresses the production of proinflammatory mediators TNF-α and IL-6.

Brexpiprazole (OPC-34712) is a partial agonist of human 5-hydroxytryptamine (5-HT) 5-HT1A and dopamine D2 receptors.

Brexpiprazole HCl (OPC 34712 dihydrochloride) is a new antipsychotic drug.

B355252 protects against cell death caused by glutamate-evoked oxidative stress. B355252 shows neuroprotective effect, potentiating nerve growth factor (NGF)-induced neurite outgrowth.

Map4343 is a 3-methyl ether derivative of pregnenolone. Map4343 binds to microtubule associated protein 2 (MAP2) in vitro and stimulates tubulin polymerization, resulting in enhanced neurite extension and protection of neurons from neurotoxic agents.

D-Menthol ((+)-MENTHOL) is a common compound in pharmaceutical and commercial products and a popular additive to cigarettes, it attenuates α±7 mediated Ca 2+ transients in the cell body and neurite, suggests that menthol inhibits α±7-nACh receptors in a noncompetitive manner.

Amisulpride is an antagonist of 5-HT7 receptor and dopamine D2 and D3 receptors. It modulates beta 2- arresting signaling and increases neurite outgrowth.

BT-13 is a selective agonist of glial cell line-derived neurotrophic factor (GDNF) receptor RET independently of GFLs. BT-13 promotes neurite growth from sensory neurons in vitro.

ITX3 is a specific, non-toxic, active and selective TrioN RhoGEF inhibitor with IC50 of 76 μM. ITX3 has anticancer effects, inhibits trion mediated GTP exchange on RhoG and Rac1, inhibits NGF-mediated neurite growth in PC12 cells and REF52 fibroblast structure formation induced by trion.

Lactacystin is an orally active, irreversible, and cell-permeable proteasome inhibitor (IC50 = 4.8 μM) that also inhibits the lysosomal enzyme cathepsin A. It induces apoptosis and cell cycle arrest, possesses anticancer, antiviral, and antioxidant activities, can penetrate the blood-brain barrier, and is commonly used in the construction of Parkinson’s disease and dementia models.

PH-002, an inhibitor targeting the intramolecular domain interaction of apolipoprotein (apo) E4 in neuronal cells, additionally enhances mitochondrial motility and promotes neurite outgrowth, thereby countering related impairments.

4-PivO-NMT chloride is an indole derivative-based regulator of the AMPK signaling pathway. It modulates neurogenesis or neurite outgrowth by influencing AMPK activity and holds potential for research in neurological disorders, pain, and inflammation.

GABA-A Receptor Ligand-1 (Compound 4) is a ligand for the GABA-A receptor with a pKi of 7.27. It alleviates mitochondrial dysfunction, promotes neurite outgrowth and neuronal regeneration, and demonstrates neuroprotective effects in a rat ischemic stroke model.

GSK3β-IN-2 (Compound S01) is an inhibitor of GSK3β with an IC50 of 0.35 nM. It activates the Wnt/β-catenin signaling pathway, promoting neurogenesis and neurite outgrowth. GSK3β-IN-2 reduces tau protein phosphorylation induced by Aβ at the Ser396 site, thereby decreasing neurofibrillary tangles. Furthermore, GSK3β-IN-2 improves Alzheimer's disease symptoms in a zebrafish model.

HBV-IN-44 (Compound (S)-2a) is an HBV inhibitor with an IC50 value of 23 nM against HbsAg. It exhibits minimal toxicity in HT22 cells and in the neurite outgrowth of ex vivo mouse DRG neurons.

HDAC6-IN-36 (compound 11d) is an HDAC6 inhibitor with an IC50 value of 8.64 nM. It promotes neurite outgrowth in PC12 cells without causing any toxic effects.

Lysoganglioside-GM1 (LysoGM1) ammonium is a derivative of Monosialoganglioside GM1, lacking the fatty acid component. It serves as an inhibitor of GM1 aggregation and can also inhibit the activation of Lyn as well as neurite outgrowth mediated by laminin-1. Lysoganglioside-GM1 ammonium is utilized in research on neurological disorders.

RG-239 is an orally active TGR5 agonist with an EC50 of 120 nM, significantly more potent than Betulinic acid (EC50= 1.04 μM). It exhibits much higher selectivity for TGR5 over FXRα. The compound enhances mitochondrial activity in adipocytes and promotes neurite outgrowth at higher concentrations. Additionally, RG-239 inhibits LPS-induced iNOS expression and nitrite production in Raw264.7 cells and microglia. RG-239 is applicable for research related to type 2 diabetes.

UCM-05194 (ammonium) is an agonist for the lysophosphatidic acid receptor 1 (LPA1). It induces calcium mobilization in RH7777 cells expressing LPA1, with an EC50 of 0.24 µM. In B103 rat neuroblastoma cells that overexpress LPA1, UCM-05194 (ammonium) promotes neurite retraction and cell migration. Additionally, it alleviates acetic acid-induced writhing and mechanical hyperalgesia in mice.

6-Bnz-cAMP is a PKA-selective activator. It regulates the PKA dependent signaling pathways. The proliferative signaling pathway which activated by the 6-Bnz-cAMP involves activation of the epidermal growth factor receptor and ERK1/2. Extending the duratio

KT5926 is an effective and selective inhibitor of myosin light chain kinase. KT5926 is an analogue of K-252a, which blocks all responses to NGF. KT5926 selectively inhibits nerve growth factor-dependent neurite elongation.